Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CXCR3 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD200R1L Biologics Sequence Review Report 2026: Cell surface glycoprotein CD200 receptor 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD200R1L protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCR4 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 4 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCR4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD200R1 Biologics Sequence Review Report 2026: Cell surface glycoprotein CD200 receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD200R1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR8 Biologics Sequence Review Report 2026: C-C chemokine receptor type 8 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR9 Biologics Sequence Review Report 2026: C-C chemokine receptor type 9 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCRL2 Biologics Sequence Review Report 2026: C-C chemokine receptor-like 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCRL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR4 Biologics Sequence Review Report 2026: C-C chemokine receptor type 4 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR3 Biologics Sequence Review Report 2026: C-C chemokine receptor type 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR5 Biologics Sequence Review Report 2026: C-C chemokine receptor type 5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CCR6 Biologics Sequence Review Report 2026: C-C chemokine receptor type 6 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR2 Biologics Sequence Review Report 2026: C-C chemokine receptor type 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
264
265
266
267
268
>>
1670
>